Results 41 to 50 of about 15,205 (209)
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023 Background PARAGON‐HF (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction) suggested a potential benefit of sacubitril–valsartan in women with preserved ejection ...
Zahra N. Sohani +4 more
doaj +1 more source
Sacubitril/valsartan:beyond natriuretic peptides [PDF]
, 2017 Natriuretic peptides, especially B-type natriuretic peptide (BNP), have primarily been regarded as biomarkers in heart failure (HF). However, they are also possible therapeutic agents due to potentially beneficial physiological effects.
Atlas +48 more
core +2 more sources
Risk related to pre–diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial [PDF]
, 2016 Background—The prevalence of pre–diabetes mellitus and its consequences in patients with heart failure and reduced ejection fraction are not known.
Cardoso, José Silva +17 more
core +1 more source
Review Article : Sacubitril/valsartan use for the hospitalist [PDF]
, 2017 The mainstays of therapy for heart failure with reduced ejection fraction (HFrEF) have traditionally been angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), beta-blockers, aldosterone receptor antagonists, and ...
Hart, James +2 more
core +1 more source
Sacubitril and valsartan fixed combination to reduce heart failure events in post-acute myocardial infarction patients [PDF]
, 2017 Heart failure is a term used to define a constellation of symptoms and signs that are commonly attributed to the inability of the heart to produce a cardiac output that meets the demands of the body. It remains a deadly disease, affecting between 1-2% of
Lang, C. C., Zaid Iskandar, M.
core +2 more sources
Principles of focused ultrasound [PDF]
, 2018 Focused ultrasound (FUS/HIFU) relies on ablation of pathological tissues, by delivering sufficiently high level of acoustic energy in situ of the human body. Magnetic Resonance guided FUS (MRgFUS/HIFU) and Ultrasound guided (USgFUS/HIFU) are image guided
Melzer, Andreas, Mihcin, Senay
core +2 more sources
ESC Heart Failure, 2021 Aims Sacubitril/valsartan combines renin–angiotensin–aldosterone system inhibition with amplification of natriuretic peptides. In addition to well‐described effects, natriuretic peptides exert direct effects on pulmonary vasculature.
Jeffrey S. Tran +9 more
doaj +1 more source
Type of atrial fibrillation and clinical outcomes in patients with heart failure and reduced ejection fraction [PDF]
, 2017 Background: Atrial fibrillation (AF) is common in heart failure (HF), but the outcome by type of AF is largely unknown. Objectives: This study investigated outcomes related to type of AF (paroxysmal, persistent or permanent, or new onset) in 2 ...
Abraham, William T. +11 more
core +3 more sources
What can we learn from SOCRATES: more questions than answers? [PDF]
, 2017 This editorial refers to ‘Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) Study’, by B ...
Cleland, John G.F., Mueller, Christian
core +1 more source
ESC Heart Failure, 2021 Aims Ivabradine and sacubitril/valsartan are second‐line therapies for patients with heart failure and reduced ejection fraction (HFrEF) based on guideline recommendations. We aimed to evaluate the synergistic effects of these two medications.
Ying‐Hsiang Lee +9 more
doaj +1 more source